# AFM13 in Relapsed/Refractory Cutaneous Lymphomas

> **NCT03192202** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ahmed Sawas** · enrollment: 18 (actual)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous

## Interventions

- **DRUG:** AFM13

## Key facts

- **NCT ID:** NCT03192202
- **Lead sponsor:** Ahmed Sawas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-04-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192202, "AFM13 in Relapsed/Refractory Cutaneous Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03192202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*